William Cance, MD, FACS, Surgeon-in-Chief and Chair of the Department of Surgical Oncology at RPCI, was interviewed by WCBS-FM Newsradio 880’s Pat Farnack. The segment aired February 10, 2011, and is also available on the New York City radio station’s website at http://newyork.cbslocal.com/audio-on-demand/health-and-well-being/#.
Dr. Cance talked about CureFAKtor Pharmaceuticals, LLC, a Roswell Park spinoff company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, and the recent news that CureFAKtor’s lead compound, CFAK-C4, has been granted “orphan drug” designation by the U.S. Food and Drug Administration (FDA). Orphan status is given to compounds being developed to treat rare medical conditions.
Annie Deck-Miller, Senior Media Relations Manager